Unknown

Dataset Information

0

Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.


ABSTRACT: Targeting dysregulated Ca2+ signaling in cancer cells is an emerging chemotherapy approach. We previously reported that store-operated Ca2+ entry (SOCE) blockers, such as RP4010, are promising antitumor drugs for esophageal cancer. As a tyrosine kinase inhibitor (TKI), afatinib received FDA approval to be used in targeted therapy for patients with EGFR mutation-positive cancers. While preclinical studies and clinical trials have shown that afatinib has benefits for esophageal cancer patients, it is not known whether a combination of afatinib and RP4010 could achieve better anticancer effects. Since TKI can alter intracellular Ca2+ dynamics through EGFR/phospholipase C-γ pathway, in this study, we evaluated the inhibitory effect of afatinib and RP4010 on intracellular Ca2+ oscillations in KYSE-150, a human esophageal squamous cell carcinoma cell line, using both experimental and mathematical simulations. Our mathematical simulation of Ca2+ oscillations could fit well with experimental data responding to afatinib or RP4010, both separately or in combination. Guided by simulation, we were able to identify a proper ratio of afatinib and RP4010 for combined treatment, and such a combination presented synergistic anticancer-effect evidence by experimental measurement of intracellular Ca2+ and cell proliferation. This intracellular Ca2+ dynamic-based mathematical simulation approach could be useful for a rapid and cost-effective evaluation of combined targeting therapy drugs.

SUBMITTER: Chang Y 

PROVIDER: S-EPMC8836083 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.

Chang Yan Y   Funk Marah M   Roy Souvik S   Stephenson Elizabeth E   Choi Sangyong S   Kojouharov Hristo V HV   Chen Benito B   Pan Zui Z  

International journal of molecular sciences 20220203 3


Targeting dysregulated Ca<sup>2+</sup> signaling in cancer cells is an emerging chemotherapy approach. We previously reported that store-operated Ca<sup>2+</sup> entry (SOCE) blockers, such as RP4010, are promising antitumor drugs for esophageal cancer. As a tyrosine kinase inhibitor (TKI), afatinib received FDA approval to be used in targeted therapy for patients with EGFR mutation-positive cancers. While preclinical studies and clinical trials have shown that afatinib has benefits for esophage  ...[more]

Similar Datasets

2025-07-20 | GSE210156 | GEO
| S-EPMC5310762 | biostudies-literature
| S-EPMC6105003 | biostudies-literature
| S-EPMC3704220 | biostudies-literature
| S-EPMC5138832 | biostudies-literature
| S-EPMC6726250 | biostudies-literature
| S-EPMC2998048 | biostudies-other
| S-EPMC4630588 | biostudies-literature
| S-EPMC8584768 | biostudies-literature
| S-EPMC3894979 | biostudies-literature